Literature DB >> 21770241

[A metabonomic study on the treatment of diabetic nephropathy with traditional Chinese medicine tang-shen-fang].

Huan Yu1, Li Li, Qionglin Liang, Yiming Wang, Ping Li, Guoan Luo.   

Abstract

An ultra performance liquid chromatography-time of flight mass spectrometry (UP-LC/TOF MS)-based method for plasma metabolic fingerprinting analysis was established. Acquired data were analyzed by principal component analysis and orthogonal projection to latent structure-discriminant analysis. The effect of tang-shen-fang (TSF) on the treatment of diabetic nephropathy patients was evaluated. Significant changes were found after 3 and 6 months' treatment of TSF compared with placebo controls. Nineteen metabolites in plasma were identified as potential biomarkers, including lipids, fatty acids and amino acids. The present metabonomic study is helpful to grasp the changes of global metabolic networks during the treatment of TSF and to testify its clinical efficacy and understand its action mechanism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21770241     DOI: 10.3724/sp.j.1123.2011.00320

Source DB:  PubMed          Journal:  Se Pu        ISSN: 1000-8713


  3 in total

Review 1.  Future perspectives of Chinese medical formulae: chinmedomics as an effector.

Authors:  Xijun Wang; Aihua Zhang; Hui Sun
Journal:  OMICS       Date:  2012-06-26

2.  Tangshen Formula Attenuates Diabetic Nephropathy by Promoting ABCA1-Mediated Renal Cholesterol Efflux in db/db Mice.

Authors:  Peng Liu; Liang Peng; Haojun Zhang; Patrick Ming-Kuen Tang; Tingting Zhao; Meihua Yan; Hailing Zhao; Xiaoru Huang; Huiyao Lan; Ping Li
Journal:  Front Physiol       Date:  2018-04-06       Impact factor: 4.566

3.  Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.

Authors:  Xin Yang; Bingxuan Zhang; Xiaoguang Lu; Meihua Yan; Yumin Wen; Tingting Zhao; Ping Li
Journal:  BMC Complement Altern Med       Date:  2016-07-26       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.